According to #TechSci Research report, Global Haemophilia Treatment Market was valued at USD 13906 million in 2020 and is forecast to reach USD24205 million in 2026 by registering a CAGR of 9.06%. Gain More Insight: https://bit.ly/3ANFB8k Get Sample Report: https://bit.ly/3Hn7CGk Press Release: https://bit.ly/3uhqRNR Website: https://www.techsciresearch.com/ Market Research News: https://techsciblog.com/

1. MARKET INTELLIGENCE . CONSULTING
www.techsciresearch.com
GLOBAL HAEMOPHILIA TREATMENT
MARKET
FORECAST & OPPORTUNITIES
2016 – 2026

2. 2
Scope of Report
Product of Interest (POI): Haemophilia Treatment
Review Period
2016 – 2019
Base Year
2020
Estimated Year
2021
Forecast Period
2022 – 2026
Year Range
REGION
• Asia-Pacific
• Europe
• North America
• South America
• Middle East & Africa
Hemophilia is treated with replacement therapy . This involves giving or
replacing the clotting factors that are too low or missing in a patient with the
condition. Patients receive clotting factors by injection or intravenously.
Market Segmentation
TYPE
• Haemophilia A
• Haemophilia B
• Haemophilia C
PRODUCT
• Recombinant Coagulation
Factor Concentrates
• Plasma Derived Coagulation
Factor Concentrate
• Desmopressin
• Antifibrinolytics Agents
TREATMENT
• On-demand
• Prophylaxis
THERAPY
• Replacement Therapy
• ITI Therapy
• Gene Therapy

3. 3
Table of Contents
S. No. Contents Page No.
1. Product Overview (Definition of Product Type and major terminologies used in the report)
2. Research Methodology (Detailed description of the methodology used to conduct the research, Raw
data backup, list of all secondary sources, List of respondents for primary surveys)
3. Impact of COVID-19 on Global Haemophilia Treatment Market
4. Executive Summary (This chapter covers summary of the complete study.)
5. Voice Of Customer
5.1. Brand Awareness
5.2. Unmet Needs & Challenges
5.3. Factors Influencing Drug Purchase
6.
Global Haemophilia Treatment Market Outlook, 2016-2026F (This chapter includes a brief
overview of the product of interest market such as total market’s growth rate, expected growth
rate, key growth levers, leading region, top grossing product types, etc. It includes more of a
qualitative information about the market.)
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Haemophilia A, Haemophilia B, Haemophilia C)
6.2.2.
By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived
Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents)
6.2.3. By Treatment(On-demand and Prophylaxis)
6.2.4. By Therapy (Replacement Therapy, ITI Therapy and Gene Therapy)
6.2.5. By Company (2020)
6.2.6. By Region
6.3. Product Market Map

4. 4
Table of Contents
S. No. Contents Page No.
7. Asia-Pacific Haemophilia Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Product
7.2.3. By Treatment
7.2.4. By Therapy
7.2.5. By Country
7.3. Asia-Pacific: Country Analysis
7.3.1. China Haemophilia Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Product
7.3.1.2.3. By Treatment
7.3.1.2.4. By Therapy

5. 5
Table of Contents
S. No. Contents Page No.
7.3.2. India Haemophilia Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Product
7.3.2.2.3. By Treatment
7.3.2.2.4. By Therapy
7.3.3. Japan Haemophilia Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Product
7.3.3.2.3. By Treatment
7.3.3.2.4. By Therapy

6. 6
Table of Contents
S. No. Contents Page No.
7.3.4. South Korea Haemophilia Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Product
7.3.4.2.3. By Treatment
7.3.4.2.4. By Therapy
7.3.5. Australia Haemophilia Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Product
7.3.5.2.3. By Treatment
7.3.5.2.4. By Therapy

7. 7
Table of Contents
S. No. Contents Page No.
8. Europe Haemophilia Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Product
8.2.3. By Treatment
8.2.4. By Therapy
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Haemophilia Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Product
8.3.1.2.3. By Treatment
8.3.1.2.4. By Therapy

8. 8
Table of Contents
S. No. Contents Page No.
8.3.2. Germany Haemophilia Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Product
8.3.2.2.3. By Treatment
8.3.2.2.4. By Therapy
8.3.3. United Kingdom Haemophilia Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Product
8.3.3.2.3. By Treatment
8.3.3.2.4. By Therapy

9. 9
Table of Contents
S. No. Contents Page No.
8.3.4. Italy Haemophilia Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Product
8.3.4.2.3. By Treatment
8.3.4.2.4. By Therapy
8.3.5. Spain Haemophilia Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Product
8.3.5.2.3. By Treatment
8.3.5.2.4. By Therapy

10. 10
Table of Contents
S. No. Contents Page No.
9. North America Haemophilia Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Product
9.2.3. By Treatment
9.2.4. By Therapy
9.2.5. By Country
9.3. North America: Country Analysis
9.3.1. United States Haemophilia Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Product
9.3.1.2.3. By Treatment
9.3.1.2.4. By Therapy

11. 11
Table of Contents
S. No. Contents Page No.
9.3.2. Canada Haemophilia Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Product
9.3.2.2.3. By Treatment
9.3.2.2.4. By Therapy
9.3.3. Mexico Haemophilia Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Product
9.3.3.2.3. By Treatment
9.3.3.2.4. By Therapy

12. 12
Table of Contents
S. No. Contents Page No.
10. South America Haemophilia Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Product
10.2.3. By Treatment
10.2.4. By Therapy
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Haemophilia Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1 By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Product
10.3.1.2.3. By Treatment
10.3.1.2.4. By Therapy

13. 13
Table of Contents
S. No. Contents Page No.
10.3.2. Argentina Haemophilia Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1 By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Product
10.3.2.2.3. By Treatment
10.3.2.2.4. By Therapy
10.3.3. Colombia Haemophilia Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1 By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.2.2.2. By Product
10.3.2.2.3. By Treatment
10.3.2.2.4. By Therapy

14. 14
Table of Contents
S. No. Contents Page No.
11. Middle East & Africa Haemophilia Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type
11.2.2. By Product
11.2.3. By Treatment
11.2.4. By Therapy
11.2.5. By Country
11.3. Middle East & Africa : Country Analysis
11.3.1 Saudi Arabia Haemophilia Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Product
11.3.1.2.3. By Treatment
11.3.1.2.4. By Therapy

15. 15
Table of Contents
S. No. Contents Page No.
11.3.2. UAE Haemophilia Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Product
11.3.2.2.3. By Treatment
11.3.2.2.4. By Therapy
11.3.3. South Africa Haemophilia Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Product
11.3.3.2.3. By Treatment
11.3.3.2.4. By Therapy

16. 16
Table of Contents
S. No. Contents Page No.
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Competitive Outlook
14.2. Company Profiles
14.2.1. Company Details
14.2.2. Product Types & Services
14.2.3. Financials (As Reported)
14.2.4. Key Market Focus & Geographical Presence
14.2.5. Recent Developments
14.2.6. Key Management Personnel
15. Strategic Recommendations
16. About Us & Disclaimer

17. RESEARCH
METHODOLOGY

18. 18
Research Methodology
 Identifying Key Opinion
Leaders
 Questionnaire Design
 In-depth Interviews
Data
Collection
Developing List
of Respondents
Formulating
Questionnaire
Market
Profiling
Data
Validation
Data
Analysis
In-depth secondary
research was conducted to
determine top players in
the global haemophilia
treatment market, overall
market size and segmental
market size.
In order to conduct
industry experts’
interviews, TechSci
formulated a detailed
discussion guide.
List of industry
players and industry
specialists was
developed.
TechSci conducted
interviews with
industry experts and
industry players for
data collection and
verification.
Data obtained as a
result of primary
and secondary
research was
validated through
rigorous
triangulation.
The data was scrutinized
using MS-Excel, statistical
tools and internal
proprietary database to
obtain qualitative and
quantitative insights about
the global haemophilia
treatment market.
Data
Collection
Data Filter
& Analysis
Research &
Intelligence
Actionable
Insights
Business
Solution
Primary Research Desk Research Company Analysis
 Recent Developments
 Market Changing
Aspects/Dynamics
 Government Policies
 Conclusion
 Market Participants
 Key Strengths
 LinkedIn
 TechSci Internal
Database
 Factiva
 Hoovers
Paid Sources
 Company Websites
 Company Annual
Reports
 White Paper Study
 Financial Reports
 Investor
Presentations
 Regulatory Body
 Associations, etc.
Secondary
Research
Primary Research

19. 19
Research Methodology
Baseline Methodology
Our dedicated team of industry experts has monitored and analyzed various aspects of the global haemophilia treatment market. The
segments of this market, while considering the major influencing factors such as haemophilia treatment. The study includes market
better decisions while planning their strategy to achieve sustainability in the global haemophilia treatment market.
Methodology Followed for Calculation of Market Size:
• Market Size by Value : Market size, in terms of value , for the year 2020 was calculated based on information collected through
exhaustive secondary research and primary surveys, with various key opinion leaders/stakeholders, such as haemophilia treatment
& end-users, industry experts, and other industry participants.
• The team interviewed more than 15 – 20 haemophilia treatment companies, 100 – 120 end-users, and 15 – 20 industry experts and
haemophilia treatment market to obtain the overall market size from 2016 to 2020, which was validated by the Delphi technique.
market size was averaged out, to arrive at the market size data during 2016-2020.

20. 20
Research Methodology
• Respondents were asked about the current and future market growth rates, market shares by type, by product, by treatment, by therapy, by company and by region. Removing the
outlier responses, the geometric mean of growth estimates and provider wise revenue shares generated across various segments were considered, to arrive at the final revenue
shares. Revenue shares generated across various segments were further triangulated from other stakeholders.
Methodology Followed for Calculation of Market Shares:
• Market share by type, by product, by treatment, by therapy, by company and by region were calculated based on the responses received through primary surveys with industry
experts, in which the respondents were asked about the market shares or revenue generated from various segments of haemophilia treatment markets. The final shares were
calculated by taking the geometric mean of the responses gathered from key opinion leaders after eliminating the outliers.
Methodology Followed for Forecasting:
• TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results in SPSS/Tableau Software.
• Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market. To forecast global haemophilia treatment market, TechSci
Research used various forecast techniques such as:
 Moving Average
 Time Series Analysis
 Regression Analysis
 Econometric and Judgmental Analysis

21. 21
Research Methodology
TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci Research also used the impact analysis during
short, medium and long term period to estimate the demand and to reach accurate market numbers. It should be noted that the figures compiled are only for the organized market
including market share data. The currency used in the report is the United States Dollar (USD), with the market size indicated in USD million.
Partial List of Companies Interviewed Key Secondary Sources
• Novo Nordisk A/S
• F. Hoffmann-La Roche AG
• Bayer AG
• Pfizer, Inc.
• Takeda Pharmaceutical Company
• Sanofi S.A.
• CSL Behring LLC
• BioMarin Pharmaceutical Inc.
• Octapharma AG
• Sangamo Therapeutics Inc.
• Eagle Pharmaceuticals Inc.
• Baxter International, Inc.
• Grifols SA
• Biogen Idec, Inc.
• Alnylam Pharmaceuticals Inc.
 World Bank
 TechSci Research Proprietary Database & Knowledge Repository
 Company Annual Reports
 Industry Magazines
 Industry Reports
 News Dailies
 Credible Paid Databases

22. 22
Industry Brief
Increasing number of haemophilic patients worldwide and increased diagnosis rate across the globe to drive global haemophilia treatment market.
According to TechSci Research report, “Global Haemophilia Treatment Market By Type (Haemophilia A, Haemophilia B, Haemophilia C), By
Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics
Agents), By Treatment (On-demand and Prophylaxis), By Therapy (Replacement Therapy, ITI therapy and Gene Therapy), By Region,
Competition, Forecast & Opportunities, 2026”, global haemophilia treatment market was valued at USD13906.45 million in 2020 and is forecast to
reach USD24205.39 million in 2026 by registering a CAGR of 9.06% during the forecast period. Increasing number of haemophilic patients worldwide is
one of the major factors accounting for the growth of global haemophilia treatment market. Moreover, upsurge in the use of prophylactic treatment for
haemophilia is expected to bode well for the growth of global haemophilia treatment market through the forecast period. In addition to this, supportive
initiatives plan by governments worldwide in order to commence early screening of neonates is expected to positively influence the growth of global
haemophilia treatment market in the years to come. Also, growing severity with the genetic evolution, is making headway for the growth of global
haemophilia treatment market. Furthermore, rising availability of Haemophilia drugs is also contributing to increasing market growth. However, there are
certain factors that might hamper the growth of global haemophilia treatment market over the coming years including high cost of recombinant products,
stringent government regulations and serious adverse effects associated with plasma derived products.
Global haemophilia treatment market can be segmented based on type, product, treatment, therapy, company, and region. Considering the product, the market is fragmented into
recombinant coagulation factor concentrates, plasma derived coagulation factor concentrate, desmopressin, and antifibrinolytics agents. Here, the recombinant coagulation factor
concentrates segment dominated the global haemophilia treatment market in terms of largest market share in 2020 and is further anticipated to maintain its dominance during the forecast
period as well, which can be accredited to increase in production of recombinant factor concentrates to treat Haemophilia coupled with its better outcome as compared to plasma derived
coagulation factor concentrate. Moreover, enhanced safety of replacement therapy by using recombinant factor concentrates, is further boosting the segmental growth. In terms of
treatment, the market is categorized into on-demand and prophylaxis. Out of which, the prophylaxis treatment is forecast to register highest growth in the years to come on account of its
efficiency and better end results. Additionally, preference for long-term prophylaxis treatment to prevent chronic arthropathy and joint bleeding in patients with severe haemophilia, is
further contributing to the growth of the segment.
Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, Pfizer, Inc., Takeda Pharmaceutical Company, Sanofi S.A., CSL Behring LLC, BioMarin
Pharmaceutical Inc., Octapharma AG, Sangamo Therapeutics Inc., Eagle Pharmaceuticals Inc., Baxter International, Inc., Grifols SA, Biogen Idec,
Inc., Alnylam Pharmaceuticals Inc., among others are the leading players operating in global haemophilia treatment market. The players are adopting
several growth strategies to enhance the market scenario of haemophilia treatment. Other competitive strategies include mergers & acquisitions;
agreements, partnerships, and collaborations; and expansions to diverse their product portfolio in order to strengthen their market position.
“North America held the largest market share in 2020 and is further projected to dominate the global haemophilia treatment market during the next five years as well. This can be ascribed
to presence of favorable healthcare reimbursement and insurance policies in the region. Furthermore, growing demand and adoption rate of haemophilia medications is also contributing
to the growing trend. Additionally, better diagnostic techniques available in the region is anticipated to bolster the growth of global haemophilia treatment market over the coming years.
Besides, Asia Pacific is projected to register the highest growth rate during the forecast period on account of early diagnosis of the diseases in growing economies such as Japan and
India, along with rising per capita use of therapies for factor VIII and IX deficiency.”, said Mr. Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.

23. 23
Sample Data - Snapshot
Global Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F
5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
2016 2020 2021E 2026F
CAGR BY VALUE: XX% CAGR BY VALUE: XX%
North America Haemophilia Treatment Market Share, By Type, By Value, 2016–2026F
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
34%
34%
34%
34%
34%
34%
34%
34%
34%
34%
34%
2016
2017
2018
2019
2020
2021E
2022F
2023F
2024F
2025F
2026F
Haemophilia A Haemophilia B Haemophilia C
United States Haemophilia Treatment Market Share, By
Treatment, By Value, 2016–2026F
50% 50% 50% 50% 50% 50% 50% 50% 50% 50%50%
50% 50% 50% 50% 50% 50% 50% 50% 50% 50%50%
Proph
ylaxis
On-
dema
nd
United States Haemophilia Treatment Market Share, By Therapy, By
Value, 2016–2026F
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
33%
34%
34%
34%
34%
34%
34%
34%
34%
34%
34%
34%
2016
2017
2018
2019
2020
2021E
2022F
2023F
2024F
2025F
2026F
Replacement Therapy ITI Therapy Gene Therapy

24. 24
Report Ordering
Report Name: GLOBAL HAEMOPHILIA TREATMENT MARKET
FORECAST & OPPORTUNITIES
2016 – 2026
To View Sample OR Purchase Report
License Type Price
Single User License $4900
Multi-User License $5900
Custom Research License $8900

25. About Us & Disclaimer
TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research reports in
number of areas to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-quality
analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’ model of a country, regional and global
company activity and industry trends, the result is a uniquely rich evaluation of the opportunities available in the market.
Related Reports
• Precision Dosing Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, Segmented By Patient Type (Pediatrics,
Geriatrics, Patients on Polypharmacy, Patients with End Organ Dysfunction, Others), By Tools (Physiologically-Based Pharmacokinetic (PBPK)
Modeling v/s Non-Linear Mixed Effects (NLME) Modeling), By Software (Web-Based v/s Desktop-Based), By Drug Class (Antibiotics, Antimycotics,
Immunosuppressives, Antiepileptics, Antitumoral Drugs, Antidepressants, Others), By Region 2016-2026
• India NIPAH Virus Diagnostics Market By Test Type (RT-PCR v/s ELISA), By Sample (Throat & Nasal Swab, Urine, Blood, Others), By End User
(Hospitals & Clinics, Diagnostics Laboratories, Others), By Region, Competition Forecast & Opportunities, FY2027
The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely,
accurate or complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it
considers reliable and firsthand. However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible
for any errors or omissions or for the results obtained from the use of such information and especially states that it has no financial liability whatsoever to the
subscribers / users of this report. The information herein, together with all estimates and forecasts, can change without notice. All the figures provided in this
document are indicative of relative market size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require prior
approval of TechSci Research.
TechSci Research – North America
708 Third Avenue, Manhattan,
New York, United States
Tel: +1- 646- 360- 1656
Email: sales@techsciresearch.com
www.techsciresearch.com
Disclaimer
TechSci Research – Europe
54, Old brook, Bretton,
Peterborough,
United Kingdom
Email: sales@techsciresearch.com
www.techsciresearch.com
TechSci Research – Asia-Pacific
B – 44, Sector – 57, Noida, National Capital
Region, U.P. - India
Tel: +91-120-4523900
Email: sales@techsciresearch.com
www.techsciresearch.com